RemeGen Co., Ltd. (SHA: 688331, HKG: 9995) announced NMPA approval for a new indication of disitamab vedotin (RC48) – its HER2‑targeting antibody‑drug conjugate (ADC) – now approved for HER2‑low expressing breast cancer patients with liver metastases who have progressed after prior systemic therapy. This marks the fourth NMPA nod for China’s first domestically developed ADC, achieving full HER2 expression coverage (IHC 3+, IHC 2+/ISH+, IHC 2+/ISH‑, IHC 1+) in the liver metastases breast cancer population.
Regulatory Milestone
Item
Detail
Product
Disitamab vedotin (RC48) – HER2‑targeted ADC
Company
RemeGen Co., Ltd. (HKG: 9995)
New Indication
HER2‑low (IHC 1+ or IHC 2+/ISH‑) unresectable/metastatic breast cancer with liver metastases
Patient Criteria
Prior systemic therapy in metastatic setting, or relapse ≤12 months post‑adjuvant chemotherapy
Approval Basis
Phase III RC48‑C012 trial (randomized, open‑label, parallel‑controlled, multicenter)
Strategic Significance
Full HER2 expression coverage for breast cancer liver metastases; fourth NMPA approval
Approved Indications Portfolio – RC48
Approval Date
Indication
HER2 Status
Tumor Type
2021
HER2‑overexpressing locally advanced/metastatic gastric cancer
First approved HER2‑targeted therapy for HER2‑low with liver mets in China
Competitive Dynamics
Trastuzumab deruxtecan (DS‑8201, Daiichi/AZ) approved HER2‑low breast cancer globally; not yet China‑approved for this indication
China first‑mover advantage in HER2‑low liver metastases segment
Commercial & Strategic Outlook
China ADC Market Leadership: RC48’s fourth indication validates RemeGen’s domestic ADC platform (vs. in‑licensing dependency); cumulative approvals demonstrate regulatory execution capabilities and clinical data quality; “first home‑grown ADC” positioning supports government preference and NRDL negotiation leverage.
HER2‑Low Expansion Trajectory: HER2‑low indication doubles addressable breast cancer population vs. HER2‑positive‑only label; liver metastases specificity targets high‑value, poor‑prognosis subset with limited effective options; potential for label expansion to all HER2‑low metastatic breast cancer (without liver mets restriction) pending additional Phase III data.
Global Partnership Potential: Seagen (now Pfizer) acquired ex‑Asia rights to RC48 (urothelial carcinoma) in 2021; HER2‑low breast cancer data strengthens global valuation for remaining RemeGen‑retained rights; potential US/EU partnership for HER2‑low indication with US$500 million‑1 billion upfront value.
Revenue Projections: Assuming RMB800 million‑1.2 billion annual RC48 sales (2026‑2027) across all indications; HER2‑low breast cancer contributes 25‑30% of volume with premium pricing vs. gastric/urothelial; NRDL inclusion (2024‑2025) enables hospital access and volume scaling.
Forward‑Looking Statements This brief contains forward‑looking statements regarding commercialization expectations, label expansion potential, and partnership opportunities for disitamab vedotin. Actual results may differ due to competitive dynamics with DS‑8201, reimbursement negotiations, and manufacturing capacity constraints.-Fineline Info & Tech
By Fineline Cube 